Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00778401 · ClinicalTrials.gov registry record · NA
Bioequivalence Study of Gabapentin 800 mg Tablets Under Fasting Conditions
A NA study, sponsored by Ranbaxy Laboratories Limited.
- Completed
- Registry status
- NA
- Development phase
- 28
- Enrollment target
NCT00778401: Completed NA study, sponsored by Ranbaxy Laboratories Limited.
NCT00778401 is a NA study that has completed, run by Ranbaxy Laboratories Limited. The registered enrollment target is 28 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00778401, a NA study, has completed, sponsored by Ranbaxy Laboratories Limited.
- COMPLETED
- Registry status
- NA
- Development phase
- 28 participants
- Enrollment target
Study Summary
This study compared the relative bioavailability (rate and extent of absorption) of the test Gabapentin tablets 800 mg by Ranbaxy Laboratories Limited to the reference Neurontin ® 800 mg tablets of Parke Davis Pharmaceuticals Ltd., distributed by Parke Davis, division of Warner-Lambert Co. in 28 healthy, adult subjects (21 males and 7 females) under fasting conditions using randomized, two-way crossover design.
Interventions
- DRUG Gabapentin tablets 800 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2002-10 |
| Est. Completion | 2002-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00778401
The ClinicalTrials.gov registry entry for NCT00778401 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ranbaxy Laboratories Limited, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Gabapentin tablets 800 mg is the first listed.
NCT00778401 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00778401 about?
NCT00778401 is a clinical study titled "Bioequivalence Study of Gabapentin 800 mg Tablets Under Fasting Conditions". This study compared the relative bioavailability (rate and extent of absorption) of the test Gabapentin tablets 800 mg by Ranbaxy Laboratories Limited to the reference Neurontin ® 800 mg tablets of Parke Davis Pharmaceuticals Ltd., distributed by Parke Davis, division of Warner-Lambert Co. in 28 hea...
What is the current status of trial NCT00778401?
This trial is currently completed. It is a NA study. The enrollment target is 28 participants. The study started on 2002-10. Estimated completion is 2002-12.
What interventions are being tested in trial NCT00778401?
The interventions under investigation include: Gabapentin tablets 800 mg (DRUG).
Who is sponsoring clinical trial NCT00778401?
This trial is sponsored by Ranbaxy Laboratories Limited, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.